Merck news from FiercePharma
NewsMerck layoffs inspire poets to versify
Curious what one laid-off Merck rep thinks about the Read more...
FDA panel rejects broader Fentora use
No go, Fentora. An FDA advisory panel voted against broadening the use of Cephalon's painkiller, Read more...
U.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related Read more...
Merck to cut 1,200 sales reps
The axeman cometh to Merck's sales force. The drugmaker plans to lop off about 15 percent in the sales ranks, or 1,200 jobs. The fact that it's not alone in trimming back on reps--Wyeth just Read more...
Pfizer starts settling Celebrex claims
Pfizer is starting to settle the thousands of lawsuits over painkillers Celebrex and Bextra, the Wall Street Journal reports. Three groups of plaintiffs who allege that the meds caused heart attacks Read more...
Vagelos: Cut prices to cure 'black eye'
Pharma needs to slap some raw steak on its black eye, Dr. Roy Vagelos said during a speech last week. Pharma's elder statesman--and ex-Merck CEO--says the drug industry has lost goodwill and Read more...
Merck CEO: 'I can't blame the media'
A triad of Merck news today, including one item about the news. We'll start with that: CEO Dick Clark (photo) Read more...
DTC hearing has high-powered guest list
Hail, hail the gang's all here...at the House Subcommittee on Oversight and Investigations hearing on direct-to-consumer ads. Next week, Rep. Bart Stupak will preside over testimony from Pfizer, Read more...
Merck warned on vaccine plant problems
Last week, we heard the warning would be coming. And here it is. The FDA has Read more...
Where Merck loses, Abbott gains
What's bad for Merck is good for Abbott Labs. When the FDA said "no" to Read more...
| Press ReleasesCelera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets /10/2008 ALAMEDA, Calif. -- Celera, an Applera Corporation business, today announced a two year exclusive Read more... Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose Read more... Merck Sells Pennsylvania Chemicals Plant Merck Sells Pennsylvania Chemicals Plant PHILADELPHIA, Jan. 1 -- PRWT Services, Inc., a minority-owned business enterprise, today announced that it has, through its wholly-owned subsidiary, Cherokee Read more... PRESS RELEASE: Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal CAMBRIDGE, Mass. -- Idera Pharmaceuticals announced today that it has entered into a worldwide licensing and collaboration Read more... PRESS RELEASE: Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX WHITEHOUSE STATION, N.J., Dec. 12, 2007 - Merck & Co., Inc. announced today that the Company has initiated a voluntary Read more... |
Get more Merck coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight